IP Library Granted Patent US 10,214,508
Granted Patent B2
US 10,214,508 · App. 15/318,552 · Granted Feb 26, 2019

Nitrogen-containing heterocyclic compound

Inventors: Masaki Ogino (Kanagawa, JP); Eiji Kimura (Kanagawa, JP); Shinkichi Suzuki (Kanagawa, JP); Tomoko Ashizawa (Kanagawa, JP); Toshihiro Imaeda (New York, NY); Ikuo Fujimori (Kanagawa, JP); Ryosuke Arai (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D401/10A61K31/44A61K31/444A61K31/4439C07D213/81C07D401/14C07D405/12C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,214,508
App. No.
15/318,552
Granted
Feb 26, 2019
Kind
B2
Abstract

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Claims (35)

1. A compound represented by the formula (I):

wherein

A is

a C 3-10 cycloalkyl group

which is optionally further substituted by 1 to 3 substituents selected from

(1) a halogen atom,

(2) a C 1-6 alkyl group optionally substituted by 1 to 3 hydroxy groups, and

(3) a C 1-6 alkoxy group;

R 1 is a hydrogen atom or a hydroxyl group;

R 2 is a hydrogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group;

R 3 is a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, a C 2-6 alkenyl group, a C 3-6 cycloalkyl group, or a C 1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms;

R 4 is a hydrogen atom or a halogen atom;

R 5 is a pyrazolyl group optionally substituted by 1 to 3 C 1-6 alkyl groups; and

X is CH,

or a salt thereof.

2. The compound according to claim 1 , wherein A is

a C 3-10 cycloalkyl group;

R 1 is a hydroxyl group;

R 2 is a hydrogen atom or a C 1-6 alkyl group;

R 3 is a halogen atom, a cyano group, a C 1-6 alkyl group, or a C 1-6 alkoxy group;

R 4 is a hydrogen atom;

R 5 is a pyrazolyl group optionally substituted by 1 to 3 C 1-6 alkyl groups; and

X is CH,

or a salt thereof.

3. The compound according to claim 1 , wherein A is a C 3-10 cycloalkyl group;

R 1 is a hydroxyl group;

R 2 is a hydrogen atom or a C 1-6 alkyl group;

R 3 is a C 1-6 alkyl group;

R 4 is a hydrogen atom;

R 5 is a pyrazolyl group optionally substituted by 1 to 3 C 1-6 alkyl groups; and

X is CH,

or a salt thereof.

4. N-((1S,2S)-2-hydroxycyclopentyl)-5-methyl-4-(4-(1-methyl-1H-pyrazol-3-yl)benzyl)pyridine-2-carboxamide or a salt thereof.

5. N-((1S,2S)-2-hydroxycyclopentyl)-5,6-dimethyl-4-(4-(1-methyl-1H-pyrazol-3-yl)benzyl)pyridine-2-carboxamide or a salt thereof.

6. A pharmaceutical composition comprising the compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2017
From: OGINO, MASAKI; KIMURA, EIJI; SUZUKI, SHINKICHI; ASHIZAWA, TOMOKO; IMAEDA, TOSHIHIRO; FUJIMORI, IKUO; ARAI, RYOSUKE
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 041372/0984 →
Priority Claims (1)
JP 2014-122919 · Jun 13, 2014 · national
Continuity (1)
Related Publication 20170121308A1 · May 4, 2017
Cited By (1)
US 12,378,256